Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

Open access
Ocean, Allyson J., Starodub, Alexander N., Bardia, Aditya, Vahdat, Linda T., Isakoff, Steven J., Guarino, Michael, Messersmith, Wells A., Picozzi, Vincent J., Mayer, Ingrid A., Wegener, William A., Maliakal, Pius, Govindan, Serengulam V., Sharkey, Robert M., Goldenberg, David M.·2017·Cancer

Abstract

BACKGROUND: Sacituzumab govitecan (IMMU‐132), an antitrophoblastic cell‐surface antigen (anti‐Trop‐2) humanized antibody‐SN‐38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU‐132 at doses of 8 or 10 mg/kg in patients with diverse advanced epithelial cancers. METHODS: Patients who had multiple prior therapies received IMMU‐132 on days 1 and 8 of 21‐day treatment cycles. Trop‐2 staining of archived tumor specimens, clearance of IMMU‐132 and its constituents (ie, immunoglobulin G [IgG], SN‐38 [a camptothecin, the active component of irinotecan], and glucuronidated SN‐38 [SN‐38G]), antibody responses, and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) levels were determined. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0, and responses were assessed using Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Patients with diverse metastatic cancers who received IMMU‐132 at 8 mg/kg (n = 81) and 10 mg/kg (n = 97) were examined. Trop‐2 was positive in 93% of the available specimens. IMMU‐132 cleared with a half‐life of approximately 11 to 14 hours, reflecting the release of SN‐38 from the conjugate; IgG cleared more slowly (half‐life, approximately 103‐114 hours). Most SN‐38 in the serum (>95%) was bound to IgG. SN‐38G concentrations were lower than SN‐38 concentrations. Dose‐limiting neutropenia after the first cycle was not correlated with SN‐38 in serum or with UGT1A1 genotype. No antibody responses were detected. Objective responses were observed in several indications, including metastatic triple‐negative breast cancer, confirming that 10 mg/kg produced an encouraging overall response. CONCLUSIONS: Sacituzumab govitecan has a predictable pharmacokinetic profile and manageable toxicity at doses of 8 and 10 mg/kg. With objective responses and a good therapeutic index at 10 mg/kg, this dose was chosen for future development. Cancer 2017;123:3843–3854. © 2017 American Cancer Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.30789

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 244

Metadata

Authors
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., Maliakal, P., Govindan, S. V., Sharkey, R. M., & Goldenberg, D. M.
Venue
Cancer
Publisher
Wiley
Published
2017-05-30
Volume
123
Issue
19
Pages
3843-3854
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2616923195
Cited by
244
References
3
FWCI
10.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. https://app.cochat.ai/papers/10.1002/cncr.30789
The paper
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., Maliakal, P., Govindan, S. V., Sharkey, R. M., & Goldenberg, D. M. (2017). Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. https://doi.org/10.1002/cncr.30789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.